Cocrystal Pharma Announces Exclusive Worldwide License And Collaboration Agreement With Merck To Develop Influenza A/B Agents; Cococrystal Will Receive Upfront Payment On An Undisclosed Amount, Is Eligible For Up To $156M In Milestones Plus Royalties